Please Wait...

Study Points Way to Increased Efficacy in Respiratory Syncytial Virus Vaccine

Respiratory syncytial virus (RSV) is increasingly being recognized as an important cause of disease in older adults worldwide. Its impact is estimated to be comparable to or even greater than that of influenza. However, RSV is not typically tested for, as there is no specific treatment. A successful vaccine would represent a vital breakthrough, deeply benefiting this growing segment of the population.

To that end, a double-blind phase 1 study was conducted with subjects 60 years of age and older. The subjects received vaccines containing escalating doses of soluble RSV fusion protein(sF) alone or adjuvanted with glucopyranosyl lipid A, a toll-like receptor-4 agonist, in 2% stable emulsion (GLA-SE). The full report of the study with its conclusions can be read in here.

One of the authors of this key study is Craig Curtis, MD, CPI, and Chief Medical Officer at Bioclinica. Dr. Curtis is a Florida-licensed physician with Board Certification in Family Medicine. He has over 15 years of clinical trial experience covering all phases of research and numerous therapeutic areas. He has served as Principal Investigator on over 200 trials in the areas of general medicine, psychiatry, neurology, analgesia, and early clinical development.

Dr. Curtis is a member of the Association of Clinical Research Professionals (ACRP), the Drug Information Association (DIA), and the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He earned his medical degree from Northeastern Ohio University College of Medicine.

Read the study now:
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-likereceptor-4 agonist and stable emulsion adjuvant

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen